Trial · NCT00602290
Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
NCT00602290, Phase 4, Completed, University of California, Los Angeles; results first posted 2014-09-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression. Trials, record NCT00602290. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00602290
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
- NCT number
- NCT00602290
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 181 participants, actual
- Lead sponsor
- University of California, Los Angeles
- Conditions
- Depression
- Interventions
- Citalopram, Methylphenidate (MPH), Placebo
- First posted
- 2008-01-28
- Last updated
- 2018-01-11
- Results first posted
- 2014-09-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16 | Maintained response measured at Week 16 | The Hamilton Depression Rating Scale (HDRS) is a 24-item depression scale and the total score is summed with a minimum score=0 and maximum score=76. There are no subscales and the higher values represent a worse outcome. Outcomes are measured and defined as follows: 1) Response will be defined as HDRS scores of 10 or less; 2) Sustained response will be defined as maintained response at week 16; 4) Remission will be defined as HDRS scores of 6 or less. |
| Secondary | Quality of Life Assessment | Measured at Baseline and Week 16 | The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a 16 item self-administered questionnaire that captures life satisfaction over the past week. Each question is rated on a 5 point scale from 1 (Very Poor) to 5 (Very Good). The total score is reported for items 1-14. The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 with higher values representing a better outcome. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16 | Maintained response measured at Week 16 | units on a scale | MEAN | |
| SECONDARY | Quality of Life Assessment | Measured at Baseline and Week 16 | The overall analyzed at baseline and week 16 differs due to participant drop out. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16 | 1 - Citalopram + Placebo | 18.3 | Standard Deviation 5.2 | units on a scale | |
| Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16 | 2 - Methylphenidate + Placebo | 18.7 | Standard Deviation 5.1 | units on a scale | |
| Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16 | 3 - Methylphenidate + Citalopram | 19.8 | Standard Deviation 6.3 | units on a scale | |
| Quality of Life Assessment | 1 - Citalopram + Placebo | Baseline | 45.50 | Standard Deviation 7.59 | units on a scale |
| Quality of Life Assessment | 2 - Methylphenidate + Placebo | Baseline | 47.06 | Standard Deviation 8.43 | units on a scale |
| Quality of Life Assessment | 3 - Methylphenidate + Citalopram | Baseline | 47.52 | Standard Deviation 7.32 | units on a scale |
| Quality of Life Assessment | 1 - Citalopram + Placebo | Week 16 | 54.45 | Standard Deviation 7.54 | units on a scale |
| Quality of Life Assessment | 2 - Methylphenidate + Placebo | Week 16 | 53.54 | Standard Deviation 13.11 | units on a scale |
| Quality of Life Assessment | 3 - Methylphenidate + Citalopram | Week 16 | 57.79 | Standard Deviation 9.19 | units on a scale |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 1 - Citalopram + Placebo | 48 | |
| Overall Study | STARTED | 2 - Methylphenidate + Placebo | 48 | |
| Overall Study | STARTED | 3 - Methylphenidate + Citalopram | 47 | |
| Overall Study | COMPLETED | 1 - Citalopram + Placebo | 46 | |
| Overall Study | COMPLETED | 2 - Methylphenidate + Placebo | 46 | |
| Overall Study | COMPLETED | 3 - Methylphenidate + Citalopram | 46 | |
| Overall Study | NOT COMPLETED | 1 - Citalopram + Placebo | 2 | |
| Overall Study | NOT COMPLETED | 2 - Methylphenidate + Placebo | 2 | |
| Overall Study | NOT COMPLETED | 3 - Methylphenidate + Citalopram | 1 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Reduced salivation | Gastrointestinal disorders | 1 - Citalopram + Placebo | 3 | 48 | |
| other | Reduced salivation | Gastrointestinal disorders | 2 - Methylphenidate + Placebo | 9 | 48 | |
| other | Reduced salivation | Gastrointestinal disorders | 3 - Methylphenidate + Citalopram | 4 | 47 | |
| serious | death | Renal and urinary disorders | 1 - Citalopram + Placebo | 1 | 48 | |
| serious | death | Renal and urinary disorders | 2 - Methylphenidate + Placebo | 0 | 48 | |
| serious | death | Renal and urinary disorders | 3 - Methylphenidate + Citalopram | 0 | 47 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 1 - Citalopram + Placebo | ||
| Total, all-cause mortality | 2 - Methylphenidate + Placebo | ||
| Total, all-cause mortality | 3 - Methylphenidate + Citalopram | ||
| Total, other adverse events | 1 - Citalopram + Placebo | 3 | 48 |
| Total, other adverse events | 2 - Methylphenidate + Placebo | 9 | 48 |
| Total, other adverse events | 3 - Methylphenidate + Citalopram | 4 | 47 |
| Total, serious adverse events | 1 - Citalopram + Placebo | 1 | 48 |
| Total, serious adverse events | 2 - Methylphenidate + Placebo | 0 | 48 |
| Total, serious adverse events | 3 - Methylphenidate + Citalopram | 0 | 47 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH077650 | Methylphenidate Use to Improve Outcomes in Geriatric Depression | LAVRETSKY, HELEN | UNIVERSITY OF CALIFORNIA LOS ANGELES | NATIONAL INSTITUTE OF MENTAL HEALTH | 2008 to 2012 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00602290
GET https://conductscience.org/api/trials/v1/NCT00602290/registered